CO-OPTIV-SECURITY
30.5.2019 17:07:07 CEST | Business Wire | Press release
Optiv Security, a global cybersecurity integrator delivering end-to-end cybersecurity solutions, has been recognized with the second highest score in the current offering category for cybersecurity incident response services by Forrester Research. The Forrester WaveTM : Cybersecurity Incident Response Services, Q1 2019 identifies Optiv as having received the highest possible score for the criteria of incident preparation, post-incident reporting and support, and average hours per response.
The report cites that “Optiv … has an excellent current offering,” noting that “it has a well-stated engagement model, and its postmortem deliverables include remediation road maps to help clients avoid repeat occurrences, and its client references were positive across the board.” The report also states that “Optiv would be a good choice from incident preparation through remediation.”
“Today’s business decision makers are faced with driving technology, product, and business growth, while being simultaneously tasked with maintaining cyber resilient programs that are ready to react, respond to, and recover from adverse events,” said Bill Young, Optiv’s vice president and general manager of advisory threat management. “Achieving cyber resiliency requires a strategy that leverages security best practices, including proactive incident management planning, programmatic penetration testing, effective detection and response capabilities, and real-time tailored threat intelligence. By addressing enterprise cybersecurity needs from the perspective of the enemy, organizations can create more successful cyber resilient programs that are built on factual-based offensive security testing.”
Young continued, “Optiv is in a unique position in the industry to provide clients with unmatched insight, depth and breadth of services, as well as a bench that extends throughout the complete ‘plan, build, run’ cybersecurity lifecycle. We are focused on enabling our clients to move from putting out fires to preventing threat actor actions and enabling their businesses. We do this by helping organizations create, prepare, and execute incident response strategies that are honed and practiced as their organizations change, providing skilled and experienced resources to augment internal staff, and delivering supporting services, such as threat hunting and forensics capabilities that help reduce breach levels and data loss. We believe receiving the second highest score in the current offering category from Forrester validates our unique approach and the positive impact we have on our clients’ operations.”
Optiv’s enterprise incident management services help organizations reduce the likelihood of attacks or incidents, secure their environments against threats, and recover from incidents while minimizing disruption. Optiv’s full suite of EIM services can be purchased in structures aligned to the clients’ business model, thereby enabling organizations to:
- Prepare – identify gaps in incident management strategy, hunt for and detect unknown threats within their infrastructure, document key personnel and escalation steps, validate and test response efforts for incidents and identify next steps to become more resilient.
- Respond During and Post Incident – uncover attackers’ actions, detail the scope of a compromise, identify steps to remove active threats found in their environments, limit data loss, and improve security controls.
- Maintain – ensure they are in a continual state of readiness for unexpected attacks or incidents with Optiv experts who are on-call and available 24x7x365. Optiv’s security and malware professionals examine clients’ systems for indicators of compromise, conduct analysis informed by a vast proprietary knowledge store of malicious code, signatures and attacks, and provide ongoing expertise.
Please visit Optiv’s website to learn more about Optiv’s incident management services .
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn:
www.linkedin.com/company/optiv-inc
Facebook:
www.facebook.com/optivinc
YouTube:
https://www.youtube.com/c/OptivInc
Blog:
www.optiv.com/explore-optiv-insights/blog
About Optiv Security
Optiv is a global cybersecurity
solutions integrator – a “one-stop” trusted partner with a singular
focus on cybersecurity. Our end-to-end cybersecurity capabilities span
risk management and transformation, cyber digital transformation, threat
management, cyber operations, identity and data management, and
integration and innovation, helping organizations realize stronger,
simpler and more cost-efficient cybersecurity programs that support
business requirements and outcomes. At Optiv, we are modernizing
cybersecurity to enable clients to innovate their consumption models,
integrate infrastructure and technology to maximize value, achieve
measurable outcomes, and realize complete solutions and business
alignment. For more information about Optiv, please visit us at www.optiv.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005565/en/
Contact:
Jason Cook (816) 701-3374 Jason.cook@optiv.com or Brett Ater (913) 304-7683 Brett.ater@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
